Literature DB >> 16381625

Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.

Amy L Davis1, Matthew Klitus, David M Mintzer.   

Abstract

PURPOSE: Adjuvant chemotherapy for breast cancer can be associated with a variety of side effects, one of which is the induction of premature menopause in premenopausal patient. Although taxanes have increasingly been used in the adjuvant setting, there has been relatively little published on the frequency of amenorrhea related to their use. PATIENTS AND METHODS: We review records of 159 premenopausal patients receiving adjuvant chemotherapy from our practice.
RESULTS: Altogether, 51% of all patients retained menstrual function after chemotherapy.
CONCLUSION: It was observed that patients receiving adjuvant anthracycline-based chemotherapy with sequential taxane therapy did not have a higher rate of amenorrhea than those not receiving a taxane.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16381625     DOI: 10.3816/CBC.2005.n.046

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  12 in total

Review 1.  Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Rodrigo R Munhoz; Allan A L Pereira; André D Sasse; Paulo M Hoff; Tiffany A Traina; Clifford A Hudis; Ricardo J Marques
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Authors:  Pamela N Munster; Amy P Moore; Roohi Ismail-Khan; Charles E Cox; Mensura Lacevic; Margaret Gross-King; Ping Xu; W Bradford Carter; Susan E Minton
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

3.  Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Authors:  Kathryn J Ruddy; Hao Guo; William Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Clifford Hudis; Ian E Krop; Harold J Burstein; Eric P Winer; Ann H Partridge; Sara M Tolaney
Journal:  Breast Cancer Res Treat       Date:  2015-05-16       Impact factor: 4.872

4.  Hormonal therapies in young breast cancer patients: when, what and for how long?

Authors:  Alexandre Christinat; Simona Di Lascio; Olivia Pagani
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

5.  Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.

Authors:  Jeon-Hor Chen; Wei-Fan Pan; Julian Kao; Jocelyn Lu; Li-Kuang Chen; Chih-Chen Kuo; Chih-Kai Chang; Wen-Pin Chen; Christine E McLaren; Shadfar Bahri; Rita S Mehta; Min-Ying Su
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

6.  Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer.

Authors:  Leila Pourali; Ali Taghizadeh Kermani; Mohammad Reza Ghavamnasiri; Fahimeh Khoshroo; Sare Hosseini; Mehdi Asadi; Kazem Anvari
Journal:  Iran J Cancer Prev       Date:  2013

Review 7.  Fertility preservation in female cancer patients: An overview.

Authors:  Nalini Mahajan
Journal:  J Hum Reprod Sci       Date:  2015 Jan-Mar

Review 8.  Dietary Isoflavones and Breast Cancer Risk.

Authors:  Samira Ziaei; Reginald Halaby
Journal:  Medicines (Basel)       Date:  2017-04-07

Review 9.  Cancer and fertility preservation: fertility preservation in breast cancer patients.

Authors:  Theodoros Maltaris; Michael Weigel; Andreas Mueller; Marcus Schmidt; Rudolf Seufert; Franz Fischl; Heinz Koelbl; Ralf Dittrich
Journal:  Breast Cancer Res       Date:  2008-04-29       Impact factor: 6.466

10.  Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.

Authors:  Martine Berliere; Florence Dalenc; Nathalie Malingret; Anita Vindevogel; Philippe Piette; Henry Roche; Jacques Donnez; Michel Symann; Joseph Kerger; Jean-Pascal Machiels
Journal:  BMC Cancer       Date:  2008-02-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.